NCT03678883 2026-04-03
9-ING-41 in Patients With Advanced Cancers
Actuate Therapeutics Inc.
Phase 2 Active not recruiting
Actuate Therapeutics Inc.
Australian & New Zealand Children's Haematology/Oncology Group
University of New Mexico
University of Oklahoma